

The former "Wyeth Pharmaceutical Co., Ltd." changed its name to "Haleon (Suzhou) Pharmaceutical Co., Ltd." – Letter to suppliers

In July 2022, our company completed its demerger from the GSK Group to form Haleon, an independent company 100% focused on everyday health. Our leading brands are built on science, innovation and people-centricity and are trusted by millions of consumers globally. All GlaxoSmithKline Consumer Healthcare legal entities are now part of the Haleon Group and we're updating their names so they reflect our Haleon branding and independence.

Starting from 15th November 2023, the legal entity name of the former **Wyeth Pharmaceutical Co., Ltd.** has been officially changed and registered as **Haleon (Suzhou) Pharmaceutical Co., Ltd.**. The company's unified social credit code, VAT number, and registered office address remain unchanged. The business entity and legal relationships remain unchanged, and all existing orders and contracts remain valid. We kindly request your special attention to the arrangements related to this change to ensure that it does not impact our ongoing business interactions.

1. Please update our company's information in your records as soon as possible.
2. Starting today, all new documents you send to our company (including invoices, contracts, quotations, bids, delivery templates, etc.) should use our new company name.
3. Starting today, we will create new purchase orders and enter new contracts using our new company name.
4. Our invoice information has been updated as follows:

Company Name: Haleon (Suzhou) Pharmaceutical Co., Ltd.
Taxpayer Identification Number: 91320500608287425D
Address/Phone: 4 Baodai West Road, Suzhou, 0512-66055666
Banking: Citibank (China) Co., Ltd., Shanghai Branch
Banking Account: 1787581214

- Until 31st December 2023, invoices with both the former Wyeth Pharmaceutical Co., Ltd. and the current Haleon (Suzhou) Pharmaceutical Co., Ltd. headers will be accepted.
- **Starting from January 1, 2024, our company will no longer accept invoices with the former Wyeth Pharmaceutical Co., Ltd. header. Please make sure to issue invoices using our new company name.**

Any invoices with incorrect information (such as incorrect legal entity names or purchase order numbers) will be rejected and returned by the company. The company will not be responsible for any payment delays resulting from incorrect invoice information.

5. The invoice submission address remains unchanged. Please send invoices to the following address:

Recipient: Tianjin Document Management Center

Address: No. 270, ChengLinDao Road, Dongli District, Tianjin, China. / Tianjin Schick
Pharmaceutical Co., Ltd. 300163

Phone: 022-24700224/228

Email: CH.Scanning@Haleon.com

*For foreign currency (other than CNY currency) invoices, please send to your Haleon business
contactor directly instead of sending to Tianjin.

6. In addition, for suppliers providing goods for the manufacturing site of Suzhou, please follow the
instructions below:

If our current legal entity name appears on any documents/labels, please replace this by the new
legal entity name Haleon (Suzhou) Pharmaceutical Co., Ltd.

Such documents/labels include but not limited to: Invoices, Packing lists, Delivery notes, Bill of
lading Shipping Consign, Labels for boxes and drums, Certificates of Analysis, Certificate of Origin
etc.

7. Data breaches: If there are any data breaches, as referenced in your contract with the Company, these
should now be reported immediately to cdir@haleon.com instead of cstd@gsk.com.
8. Additional Information: Please note that GSK logo has been removed from new Purchase Orders from
15th July, 2023. This remains a legally valid Haleon document.

For queries about invoices or payments, please go to our [Haleon supplier portal](#) or contact your local
[Purchase-to-Pay Help Desk](#).

We sincerely apologize for any inconvenience this change may have caused you. We truly appreciate your
understanding and continued support!

Haleon (Suzhou) Pharmaceutical Co., Ltd.



- Blank Below -